Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus
- 7 March 2025
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (10)
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- French protocol for the diagnosis and management of systemic lupus erythematosusLa Revue de Médecine Interne, 2024
- Transcriptomic analysis of one patient with lupus skin lesions treated with anifrolumabJournal of the European Academy of Dermatology and Venereology, 2024
- Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic DirectionsAmerican Journal of Clinical Dermatology, 2023
- Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosusJournal of the American Academy of Dermatology, 2023
- A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusArthritis & Rheumatology, 2022
- Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosusJournal of the European Academy of Dermatology and Venereology, 2021
- Trial of Anifrolumab in Active Systemic Lupus ErythematosusNew England Journal of Medicine, 2020